Pilot Test of COVID-19 Related Clinical Outcome Assessment Methodology and Qualitative Evidence of Content Validity

NCT05207293 | Completed

• 1 other identifier: SG019
• Study Type: observational
• Target: 29
• Locations: 2 countries
• Sites: 5

Brief Summary

COVID-19 is an acute respiratory disease caused by Severe Acute Respiratory Syndrome coronavirus (SARS-CoV). Synairgen is currently conducting a global Phase III clinical trial of SNG001 to determine efficacy and safety in patients hospitalised due to COVID-19 that receive oxygen therapy. The primary endpoint in the Phase III trial (SG018) is to evaluate recovery in patients hospitalised due to COVID-19 that require oxygen therapy after administration of SNG001 compared to placebo. The primary endpoint will be determined using the World Health Organization Ordinal Scale of Clinical Improvement (OSCI) score, which will be assessed daily. The OSCI will be used in two different ways during SG018. When the patients are in hospital, the clinical study staff will assess the patient via observation using the OSCI. However, when patients have been discharged from hospital, the clinical study staff will assess the OSCI by asking two questions, one regarding the presence of COVID-19 symptoms and the other regarding usual activities returning to baseline levels. The patient will be required to answer both questions with either a 'yes' or 'no' answer. Daily assessments of the OSCI will be conducted via video call or telephone call after discharge from hospital. The two questions asked of patients when OSCI is assessed after discharge from hospital have been added to trial SG018 to allow assessment of OSCI to continue throughout the trial. As these are new questions and the data from these is being used to assess the primary endpoint in trial SG018, their relevance, ease of understanding and clarity needs to be shown, which is why this interview study is being conducted. Having patients comment on these questions will ensure that the way the benefit of treatment is being measured in SG018 is done in a robust and patient-centred way. The main aims of this qualitative pilot study are to:

1. 1.To confirm how relevant, clear and easy to understand the two additional OSCI questions asked about COVID-19 symptoms and levels of usual activity are when patients have been discharged from hospital.
2. 2.To find out what other symptoms and experiences patients hospitalised for COVID-19 might have had to see if these are reflected in the questionnaires used in SG018.

Conditions

COVID-19

Keywords

COVID-19; Ordinal Scale of Clinical Improvement; Clinical Outcome Assessment

Outcome Measures

Primary Outcomes (8)

• Confirmation of content relevance, comprehensiveness and clarity

  Confirm the content relevance, comprehensiveness and clarity of the Ordinal Scale of Clinical Improvement (OSCI) score Patient Reported Outcome assessment post hospital discharge. Two questions are answered 'Yes' or 'No' and these determine a score of either 0, 1 or 2, where the higher the score the worse the outcome.

  Within 35 days of hospital discharge

• Confirmation of content relevance, comprehensiveness and clarity

  Confirm the content relevance, comprehensiveness and clarity of the COVID-19 symptom assessment instrument. When asked if the symptom is present, the patient answers either 'yes' or 'no'. The answer 'yes' indicates a worse outcome.

  Within 35 days of hospital discharge

• Confirmation of content relevance for SG018 PRO instruments (BCSS)

  Conduct concept confirmation exercises for the breathlessness, cough and sputum scale (BCSS) (scale of 0 (no symptoms) up to 4 (severe symptoms) to demonstrate the content relevance in this patient population.

  Within 35 days of hospital discharge

• Confirmation of content relevance for SG018 PRO instruments (EQ-5D-5L)

  Conduct concept confirmation exercises for EuroQol 5-dimension 5-level (EQ-5D-5L) to demonstrate the content relevance in this patient population. The EQ-5D-5L provides a simple descriptive profile and a single index value for health status. The EQ-5D-5L self-rated questionnaire includes a visual analogue scale, which records the respondent's self-rated health status on a graduated (0-100) scale, with higher scores for higher health-related quality of life. It also includes the EQ-5D-5L descriptive system, which comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension. Here, 100 means the best health and 0 means the worst health.

  Within 35 days of hospital discharge

• Confirmation of content relevance for SG018 PRO instruments (GAD-7)

  Conduct concept confirmation exercises for the General Anxiety Disorder 7 Questionnaire (GAD-7) to demonstrate the content relevance in this patient population. Scoring will be done based on how often patients have been bothered by the problems as: feeling nervous, anxious or on edge; not being able to stop or control worrying; worrying too much about different things; trouble relaxing; being so restless that it's hard to sit still; becoming easily annoyed or irritable, and feeling afraid at if something awful might happen. The scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates nearly bothered every day by any of the above problems. Higher scores indicated worse outcome.

  Within 35 days of hospital discharge

• Confirmation of content relevance for SG018 PRO instruments (PHQ-9)

  Conduct concept confirmation exercises for the Patient Health Questionnaire-9 (PHQ-9) to demonstrate the content relevance in this patient population. Patient health questionnaire included: little interest or pleasure in doing things; feeling down, depressed or hopeless; trouble falling asleep or staying asleep, or sleeping too much; feeling tired or having little energy; poor appetite or overeating; feeling bad about yourself or that you are a failure have let yourself or your family down; trouble concentrating on things; moving or speaking so slowly or so fidgety or restless that you have been moving a lot more than usual; and thoughts that you would be better off dead; or thoughts of hurting yourself in some way. Based on responses, scoring will be done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates nearly bothered every day by any of the above problems. Higher scores indicated worse outcome.

  Within 35 days of hospital discharge

• Confirmation of content relevance for SG018 PRO instruments (FACIT)

  Conduct concept confirmation exercises for the FACIT Fatigue Scale (Version 4) (FACIT) to demonstrate the content relevance in this patient population. The FACIT Fatigue Scale (Version 4) will include statements for patients such as: I feel fatigued; I feel weak all over; I feel listless ("washed out"); I feel tired; I have trouble starting things because I am tired; I have trouble finishing things because I am tired; I have energy; I am able to do my usual activities; I need to sleep during the day; I am too tired to eat; I need help doing my usual activities; and I am frustrated by being too tired to do the things I want to do. Based on responses on above statements, scoring will be done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates very much bothered every day by any of the above problems. Higher scores indicated worse outcome.

  Within 35 days of hospital discharge

• Confirmation of content relevance for SG018 PRO instruments (BPI-SF)

  Conduct concept confirmation exercises for the Brief Pain Inventory (Short Form) (BPI-SF) to demonstrate the content relevance in this patient population. Form includes: did patient have pain other than everyday kinds of pain on assessment day; body part where patient feels pain; rate pain: at worst, at least in the last 24 hours, at average and at right now, by giving scores from 0 to 10, where 0 indicates no pain and 10 represents pain as bad as one can imagine; treatments or medications receiving for pain by patients; how much relief have pain treatments provided from 0% to 100%, where 0% represents no relief and 100% indicates complete relief; assessment of interference of pain in patients activity: general activity; mood; walking ability; normal work; relations with other people; sleep; enjoyment of life, and assessment will be done by scoring ranges from 0 to 10, where 0 represents pain does not interfere and 10 indicates pain completely interferes.

  Within 35 days of hospital discharge

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study will include up to 25 patients who have had a positive test for COVID-19 and who were hospitalised due to their COVID-19. Diagnosis of COVID-19 and hospitalization will be confirmed by study personnel. The interview will take place up to 35 days post discharge from hospital. The eligibility criteria are designed to align with the SG018 protocol to ensure that a similar population evaluates the PROs as the population who completes the instruments as part of the clinical development program.

You may qualify if:

• ≥ 18 years at the time of consent
• Must have a confirmed diagnosis of COVID-19
• Must have been discharged from hospital due to COVID-19 infection in the last 35 days
• Must exhibit reliability and physiologic capability (e.g. sufficient hearing, vision etc.) to comply with all protocol procedures, in the investigator's opinion and must have educational level of minimum 8th grade or primary school;
• \. Must be able to read, write, and speak in a local language to complete the informed consent process and participate in an interview; 7. Must be willing to provide written informed consent to participate in the study; and, 8. Must be able to participate in a one-time interview for approximately 90-120 minute via video conference (e.g., Microsoft Teams, WebEx) AND has access to the necessary equipment and internet access.

You may not qualify if:

• Signed the consent form to participate in the Synairgen SG018 clinical trial,
• Cognitive impairment, significant mental illness, or other disability impairing ability to participate in and/or complete research interview based on study coordinator's or clinician's judgement; or,
• Ongoing substance abuse disorders that may impact participation in this study.

Sponsors & Collaborators

• Synairgen Research Ltd.: lead
• Parexel: collaborator

Study Sites (5)

Henry Ford Health System

Detroit, Michigan, 48202, United States

Location

University Hospitals Dorset NHS Foundation Trust

Bournemouth, Dorset, BH7 7DW, United Kingdom

Location

Hull Royal Infirmary

Hull, East Riding Of Yorkshire, HU3 2RW, United Kingdom

Location

University Hospital Southampton NHS Foundation Trust

Southampton, Hampshire, SO16 6YD, United Kingdom

Location

Queen Elizabeth Hospital Birmingham

Birmingham, B15 2TH, United Kingdom

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 23, 2021
• First Posted: January 26, 2022
• Study Start: November 15, 2021
• Primary Completion: January 31, 2022
• Study Completion: January 31, 2022
• Last Updated: January 4, 2023

Record last verified: 2023-01

Locations

GB (4); US (1)